Tumor-associated antigen RHAMM
AssigneeLudwig Institute for Cancer Research
InventorsMichael Schmitt, Jochen Greiner
Life of this patent
Estimating the term…
Abstract
The invention provides methods for diagnosing cancer including acute myeloid leukemia and chronic myeloid leukemia, based on the identification of certain cancer-associated polypeptides as antigens that elicit immune responses in cancer. The identified antigens can be utilized as markers for diagnosing cancer, and for following the course of treatment of cancer.
Claims24
A method for diagnosing cancer in a subject comprising:
- obtaining a biological sample from a subject,
- contacting the sample with a RHAMM polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1, 2, and 3, and
- determining specific binding between the RHAMM polypeptide and agents in the sample, wherein the presence of specific binding is diagnostic for cancer in the subject.
A method for determining onset, progression, or regression, of cancer in a subject, comprising:
- obtaining from a subject at a first time a first biological sample,
- determining specific binding between agents in the first sample and a RHAMM polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1, 2, and 3, and
- obtaining from a subject at a subsequent time a second biological sample,
- determining specific binding between agents in the second sample and a RHAMM polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1, 2, and 3, and
- comparing the determination of binding in the first sample to the determination of specific binding in the second sample as a determination of the onset, progression, or regression of the cancer.
A method for selecting a course of treatment of a subject having or suspected of having cancer, comprising:
- obtaining from the subject a biological sample,
- contacting the sample with a RHAMM polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1, 2, and 3, and
- determining specific binding between agents in the sample that are differentially expressed in different types of cancer, and the RHAMM polypeptide, and
- selecting a course of treatment appropriate to the cancer of the subject.
A kit for the diagnosis of cancer in a subject, comprising:
- a RHAMM polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1, 2, and 3, and one or more control antigens;
- and instructions for the use of the polypeptide and control antigens in the diagnosis of cancer.
A protein microarray comprising of a RHAMM polypeptide, wherein the RHAMM polypeptide is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 1, 2, and 3, and fixed to a solid substrate.
Dependencies are inferred from the claim text.